an allelic frequency of between 50% and 60% in Europeans and Asians, according to large databases of control subjects.
Studying people of various genotypes, the authors demonstrate that blood cells from subjects homozygous for alleles encoding IFIH1 T946 , as well as those who carry this variant on a shared haplotype with a second IFIH1 polymorphism (rs3747517, which encodes a histidine-to-arginine substitution at position 843 (p.H843R)), express an 'interferon signature' in the resting state and have increased expression of transcripts encoding interferon-β following stimulation with the synthetic dsRNA analog poly(I:C) but blood cells from subjects homozygous for alleles encoding the non-risk (NR) variant IFIH1 A946 (called 'IFIH1 NR ' by the authors) do not. Concordant findings are obtained via overexpression of mouse IFIH1 in HEK293T human embryonic kidney cells, with an enhanced interferon state conferring increased responsiveness to RNA viral challenge (independently of any allele-determined change in protein levels). Collectively, these findings suggest that these IFIH1 polymorphisms represent a gain of function.
To study the effect of such polymorphisms in vivo, the authors develop a knock-in mouse model expressing both substitutions noted above (IFIH1 R843-T946 ; called 'IFIH1 R ' by the authors) and report that splenocytes from mice either heterozygous or homozygous for this have higher basal expression of transcripts from the gene encoding interferon-β and interferon-stimulated genes than that of cells from IFIH1 NR mice and also show protection from an IFIH1-specific viral challenge. But how can this elevated interferon signature lead to automimmune disease? To address this question, Gorman et 1 . Through studies of both human cells and mice, they define an apparently major functional effect on the response to infection and the risk of autoimmunity associated with a non-synonymous coding variant of IFIH1 found at high allelic frequency in the general population. These data are interesting in pointing the way to the study of other GWAS 'hits' and the investigation of modifying factors that might help to explain variable expression and non-penetrance in Mendelian disease (Fig. 1) .
IFIH1 is a cytosolic sensor of dsRNA that induces an anti-viral type I interferon state. Non-synonymous coding variants of IFIH1 have been associated with various autoimmune phenotypes, most particularly type 1 diabetes (T1D) 2, 3 . In the present study, the authors investigate the rs1990760 allele, which encodes an alanine-to-threonine substitution at position 946 of the protein (p.A946T; called 'IFIH1 T946 ' by the authors), which has Polymorphisms in IFIH1: the good and the bad Erika Della Mina, Mathieu P Rodero & Yanick J Crow A study of polymorphisms in the sensor IFIH1 exposes the evolutionary trade-off between a robust antiviral type I interferon response and the risk of interferon-mediated inflammation.
dose of streptozotocin that fails to elicit disease in IFIH1 NR mice, they find that IFIH1 R mice manifest T1D. Moreover, the progeny of heterozygous IFIH1 R mice crossed with mice heterozygous for a PTPN22 variant that has been associated with multiple human autoimmune phenotypes 4 also show an enhanced propensity to develop T1D. Furthermore, adoptive transfer of CD4 + T cells from a BML12 lupus model into mice heterozygous or homozygous for IFIH1 R is linked to the production of high titers of autoantibodies directed against dsDNA, Smith antigen and ribonucleoprotein, in contrast to the low antibody titers in IFIH1 NR mice. Overall, these findings indicate that IFIH1 R can promote an autoimmune state in the context of an 'environmental' trigger and in combination with additional risk alleles.
Heterozygous gain-of-function mutations in IFIH1 cause a spectrum of severe neuroinflammatory phenotypes 5 . Interestingly, clinical non-penetrance has been observed for some of these high-risk alleles, despite the presence of markedly enhanced type I interferon signaling recorded in patients' blood, which invokes modifying genetic and environmental factors. Such studies suggest that IFIH1 acts with a threshold signaling effect and allows a degree of tolerance to endogenous dsRNA ligands. In a somewhat unexpected finding, Gorman et al. observe a significant embryonic survival defect in their homozygous IFIH1 R mice, which they hypothesize might be due to enhanced sensitivity of the IFIH1 T946 substitution for selfderived dsRNA 1 . To test this possibility, they perform in vitro studies of cells expressing mutant ADAR1, a dsRNA-specific adenosine deaminase 6, 7 . Editing of adenosine residues to inosine in dsRNA is necessary to prevent sensing of self dsRNA by IFIH1. Concordantly, as for IFIH1, expression of mutant ADAR1 results in a human 'type I interferonopathy' phenotype 8 , and loss of ADAR1 activity N E w S A N D v I E w S in HEK293T cells leads to enhanced type I interferon signaling following overexpression of IFIH1. Consistent with their hypothesis, the authors observe higher expression of mRNA encoding interferon-β in ADAR1-null cells expressing mouse IFIH1 R than in cells expressing IFIH1 NR .
Taken as a whole, the results of this study suggest an evolutionary trade-off between fighting infection through a robust type I interferon response and the risk of interferon-mediated inflammation. These data chime with an interesting publication showing that the p.A946T substitution in IFIH1 confers an enhanced interferon response to coxsackievirus in human pancreatic islet cells 9 . That particular study is of note for its use of disease-relevant human cells and for mechanistically linking type III interferons to the pathogenesis of T1D 9 . Perhaps the most striking aspect of both of these reports is that a polymorphism seen at very high allelic frequency in the general population can be associated with such clear functional effects in vitro and in vivo. This situation is reminiscent of published data on the cyclic-dinucleotide sensor STING, in which a haplotype found in the homozygous state in 16% of East Asians and 2.8% of Europeans has been shown to act as a null allele in certain cell types 10 .
The embryonic lethality associated with homozygosity for the IFIH1 R haplotype is surprising and does not sit well with the possibility of positive selection for an allele that confers type-I-interferon-mediated protection against infection. Proof that this effect is truly mediated by type I interferons, which could be obtained by crossing such mice (Ifih1 R/R ) with mice lacking the adaptor MAVS, might help to clarify the situation. More generally, as for certain monogenic interferonopathies, these data raise the important question about the nature of the putative endogenous ligand(s) that can trigger IFIH1 (ref. 11).
Clinical non-penetrance is a feature of a series of dominant immunological dysregulatory diseases. Indeed, such non-penetrance might go some way toward explaining why heterozygous mutations in the genes encoding PI(3)Kδ, CTLA-4, TREX1, IFIH1, ADAR1, AIRE and COPA were defined only relatively late in the context of human clinical genetic studies. Such observations indicate redundancy in the human immune system, which is probably particularly relevant to innate immunity 12 and the action of modifying genetic factors. The study by Gorman et al. 1 is therefore interesting in providing a model with which to approach the question of GWAS signals in common disease, as well as the penetrance and expression of rare Mendelian phenotypes, which perhaps do not always rest very far apart in terms of their 'complexity' . The Hippo pathway gets its name from the 'hippopotamus' appearance caused by tissue overgrowth in hpo-mutated Drosophila, which revealed that Hippo signaling regulates cellular proliferation and survival to control organ size 3 . Hippo is also considered a tumorsuppressor pathway due to its dysregulation in tumors 3, 4 . The pathway is complex, with more than 35 proteins identified in humans, and has been extensively reviewed elsewhere 3, 4 . At its core is a kinase complex, including Mst1, that phosphorylates the downstream Hippo transcriptional regulators and inhibits their function by targeting them for proteosomal degradation or cytoplasmic sequestration.
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